We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

287% more call options, than puts

Call options by funds: $22.4M | Put options by funds: $5.79M

77% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 57

1% more capital invested

Capital invested by funds: $1.23B → $1.24B (+$18.3M)

0.61% more ownership

Funds ownership: 92.14% → 92.75% (+0.61%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

1% less funds holding

Funds holding: 236 → 233 (-3)

Holders
233
Holders Change
-3
Holders Change %
-1.27%
% of All Funds
3.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
101
Reduced
57
Closed
22
Calls
$22.4M
Puts
$5.79M
Net Calls
+$16.6M
Net Calls Change
+$3.11M

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$18.5M
2
DM
Deerfield Management
New York
+$14.1M
3
N
Nuveen
North Carolina
+$11.3M
4
BlackRock
BlackRock
New York
+$9.19M
5
Morgan Stanley
Morgan Stanley
New York
+$6.87M

Top Sellers

Rank Fund Capital Flow
1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.3M
2
State Street
State Street
Massachusetts
-$12.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.95M
4
Fisher Asset Management
Fisher Asset Management
Washington
-$8.19M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$13.1M +$109K +15,142 +0.8%
Stifel Financial
27
Stifel Financial
Missouri
$13.1M -$3.84K -535 -0%
Morgan Stanley
28
Morgan Stanley
New York
$12.9M +$6.87M +956,027 +110%
TCM
29
Tang Capital Management
California
$12.7M -$4.67M -650,000 -27%
Two Sigma Investments
30
Two Sigma Investments
New York
$12.4M +$3.05M +424,657 +32%
Alkeon Capital Management
31
Alkeon Capital Management
New York
$11.8M – – –
Goldman Sachs
32
Goldman Sachs
New York
$10.9M +$459K +63,922 +4%
Charles Schwab
33
Charles Schwab
California
$10.3M +$139K +19,402 +1%
Citadel Advisors
34
Citadel Advisors
Florida
$9.78M +$2.31M +321,309 +30%
Assenagon Asset Management
35
Assenagon Asset Management
Luxembourg
$7.86M -$30.3M -4,223,010 -79%
Bank of America
36
Bank of America
North Carolina
$7.73M -$1.92M -266,640 -20%
AllianceBernstein
37
AllianceBernstein
Tennessee
$7.69M +$6.11M +850,456 +360%
SVCM
38
Saturn V Capital Management
Texas
$6.96M +$198K +27,602 +3%
VOYA Investment Management
39
VOYA Investment Management
Georgia
$6.57M +$1.03M +142,843 +18%
First Manhattan
40
First Manhattan
New York
$6.19M – – –
Norges Bank
41
Norges Bank
Norway
$5.99M – – –
Rafferty Asset Management
42
Rafferty Asset Management
New York
$5.72M -$1.2M -167,075 -17%
SCM
43
Silverarc Capital Management
Massachusetts
$5.61M +$221K +30,767 +4%
SCM
44
Sarissa Capital Management
Connecticut
$5.49M – – –
Bank of New York Mellon
45
Bank of New York Mellon
New York
$5.43M +$58.1K +8,087 +1%
ECM
46
ExodusPoint Capital Management
New York
$5.31M -$3.32M -462,494 -38%
Squarepoint
47
Squarepoint
New York
$5.28M +$5.22M +726,378 +3,683%
PAM
48
Panagora Asset Management
Massachusetts
$5.15M +$302K +41,971 +6%
Walleye Capital
49
Walleye Capital
New York
$5.03M +$3.84M +534,472 +303%
DCM
50
DAFNA Capital Management
California
$4.62M +$596K +83,000 +15%
1
2
3 4 5

BCRX Hedge Fund Activity: Q3 2023 in Review

233 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2023, worth a combined $1.24B — up 1.5% from $1.23B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 101 added.

The largest buyer was Braidwell, adding an estimated $18.5M. The largest seller was Assenagon Asset Management, cutting an estimated $30.3M.

  • 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2023, down from 236 in Q2 2023.
  • Funds reported $1.24B of BioCryst Pharmaceuticals stock for Q3 2023, up 1.5% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2023 was Braidwell, an estimated $18.5M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2023 was Assenagon Asset Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2023.